Showing results (2101-2110 of 2,143) with videos related to

Sort By:
Pageof 215
Science (New York, N.Y.)|April 28, 2018
Field-deployable viral diagnostics using CRISPR-Cas13Cameron Myhrvold, Catherine A Freije, Jonathan S Gootenberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortRafal Dziadziuszko, Tony Mok, Solange Peters, et al.
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
DengueSeq: A pan-serotype whole genome amplicon sequencing protocol for dengue virusChantal B F Vogels, Verity Hill, Mallery I Breban, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 5, 2016
Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definitionP N A Harris, J F McNamara, D C Lye, et al.
Oncotarget|August 25, 2016
Therapeutic relevance of the protein phosphatase 2A in cancerChelsea E Cunningham, Shuangshuang Li, Frederick S Vizeacoumar, et al.
Epilepsia|March 10, 2023
Leveraging expertise and optimizing clinical research: Initial success of a pediatric epilepsy surgery collaborativeMadison M Berl, Jennifer I Koop, Alyssa Ailion, et al.
Brain & Spine|June 30, 2025
A core outcome set for cranioplasty following stroke or traumatic brain injury - The COAST studyH Mee, T K Korhonen, A M Castaño-Leon, et al.
The New England Journal of Medicine|March 19, 2020
Selumetinib in Children with Inoperable Plexiform NeurofibromasAndrea M Gross, Pamela L Wolters, Eva Dombi, et al.
BMC Genomics|May 1, 2024
DengueSeq: a pan-serotype whole genome amplicon sequencing protocol for dengue virusChantal B F Vogels, Verity Hill, Mallery I Breban, et al.
Journal for Immunotherapy of Cancer|March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Pageof 215